Primary endpoint
Two of the thirty-one blood samples collected in the heterologous arm were lost. Moreover, the serological responses of 30 patients in the homologous arm and 29 patients in the heterologous arm were compared as the primary outcome.
Scatter plot of the SARS-CoV-2 IgG immune status ratio in homologous and heterologous prime-boost arms before and after the booster dose in autologous hematopoietic stem cell transplant recipients.